LGEN:LSELegal & General Group Plc Analysis
Data as of 2026-03-11 - not real-time
£258.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Legal & General trades at a trailing P/E of 64.6 versus an industry average of 17.3 and a price‑to‑book of 781, signalling clear overvaluation despite a forward P/E of 10.7 that hints at expected earnings upside. The stock offers an attractive 8.6% dividend yield, but a payout ratio of 484% raises serious concerns about sustainability, especially given negative operating cash flow and a debt‑to‑equity ratio exceeding 1,100. Technically, the price sits below the 20‑day SMA (266.1) and the MACD is in a bearish configuration, while volume is rising and the 30‑day volatility is near 25%, suggesting short‑term pressure with limited upside of about 3% before hitting resistance at 279.5.
The company’s revenue is growing at roughly 10% and free cash flow remains strong, yet the heavy leverage, regulatory exposure inherent to the insurance and asset‑management business, and the unsustainable dividend policy temper enthusiasm. Given the low beta (≈0.3) the stock is relatively insulated from market swings, but the combination of high valuation, leverage and dividend risk points to a cautious stance, favouring a hold in the near term and a measured buy on the medium horizon if earnings materialise, while maintaining vigilance on balance‑sheet health for the long run.
The company’s revenue is growing at roughly 10% and free cash flow remains strong, yet the heavy leverage, regulatory exposure inherent to the insurance and asset‑management business, and the unsustainable dividend policy temper enthusiasm. Given the low beta (≈0.3) the stock is relatively insulated from market swings, but the combination of high valuation, leverage and dividend risk points to a cautious stance, favouring a hold in the near term and a measured buy on the medium horizon if earnings materialise, while maintaining vigilance on balance‑sheet health for the long run.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below short‑term SMA
- Unsustainable dividend payout ratio
- Limited near‑term upside versus resistance
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward P/E of 10.7 indicating earnings upside
- Revenue growth near 10% and strong free cash flow
- Increasing volume suggesting accumulating interest
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High leverage and debt‑to‑equity over 1,100
- Regulatory and sector exposure in insurance/asset management
- Persistently high valuation multiples
Key Metrics & Analysis
Financial Health
Revenue Growth9.70%
Profit Margin2.28%
P/E Ratio64.6
ROE9.49%
ROA0.10%
Debt/Equity1116.15
P/B Ratio781.0
Op. Cash Flow£-1488999936
Free Cash Flow£5.1B
Industry P/E17.3
Technical Analysis
TrendBullish
RSI45.0
Support£245.00
Resistance£279.50
MA 20£266.10
MA 50£264.90
MA 200£251.78
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair Value£1,654.00
Target Price£266.71
Upside/Downside3.17%
GradeOvervalued
TypeBlend
Dividend Yield8.60%
Risk Assessment
Beta0.32
Volatility24.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.